As of January this year, California, New Hampshire, Pennsylvania and South Carolina ended Medicaid GLP-1 drug coverage for weight loss, and Michigan started restricting coverage to people classified as morbidly obese, meaning they have a body mass index above 40
In patients converted to divalproex sodium monotherapy, the mean total valproate concentrations during monotherapy were 71 and 123 mcg/mL in the low dose and high dose groups, respectively
PMCID: PMC4446189
9% of orforglipron patients discontinued due to adverse events, compared with 5% for oral semaglutide
Prlh expression was required for the long-term suppression of food intake and body weight by cagrilintide in rats
Many doctors will consider continuing weight loss medication if youve achieved significant results, and stopping treatment might lead to weight regain